Market Cap$113.02B
P/E34.82x
PEG Ratio1.37
Div yield1.02%
Beta0.79
SYK Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-24.71%
Price vs S&P 500 (4W)8.79%
PEG Ratio1.37
VGM Score55.40
P/E Ratio (Annual)34.82x
Indicated Dividend Yield (Annual)1.02%
SYK Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $3.49 | $3.69 | +5.79%(+$0.20) | |
| Q1 2026 | $2.98 | $2.60 | -12.86%(-$0.38) | |
| Q4 2025 | $4.40 | $4.47 | +1.70%(+$0.07) | |
| Q3 2025 | $3.13 | $3.19 | +1.87%(+$0.06) | |
| Q2 2025 | $3.07 | $3.13 | +1.95%(+$0.06) |
SYK Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.14
4.14
4.21
4.15
Industry Peers — Surgical & Medical Instruments(142)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
SYKStryker Corporation | C | B | C | 4.4x | 11.8% | 65.3% | 21.3% | $294.66 |
| MMM3M Company | C | D | B | 3.4x | -5.0% | 39.4% | 18.4% | $164.75 |
| BSXBoston Scientific Corp. | C | B | C | 3.1x | 15.2% | 69.5% | 19.8% | $44.39 |
| BDXBecton, Dickinson and Co. | B | D | A | 2.5x | 6.3% | 46.7% | 9.6% | $191.75 |
| MDLNMedline Inc. Class A common stock | C | D | C | 1.6x | — | 26.2% | 6.0% | $35.96 |
| RMDResMed Inc. | C | C | B | 5.9x | 12.1% | 61.1% | 33.4% | $238.97 |
| DXCMDexCom, Inc. | C | B | B | 6.5x | 19.3% | 64.3% | 22.9% | $86.04 |
| WSTWest Pharmaceutical Services, Inc. | D | C | A | 8.5x | 7.4% | 36.8% | 20.4% | $384.02 |
| SOLVSolventum Corporation | C | C | B | 1.8x | — | 54.8% | 23.9% | $85.81 |
| BAXBaxter International Inc. | B | D | B | 1.1x | -0.8% | 30.7% | -2.3% | $25.28 |
| PENPenumbra, Inc. | F | C | B | 8.4x | 20.2% | 67.8% | 12.4% | $320.86 |
About Stryker Corporation
Stryker manufactures and markets orthopedic implants, medical devices, and hospital equipment serving surgical and patient care settings. The company holds leading market positions in reconstructive orthopedics and operating room equipment, with products including joint replacements, endoscopy systems, robotics, and hospital beds. As one of the top three reconstructive orthopedic competitors, Stryker generates approximately one-quarter of revenues internationally.